Publications in collaboration with researchers from Hospital General Universitario Gregorio Marañón (21)

2026

  1. Cost-effectiveness of personalized medical treatment in acromegaly: A post hoc analysis of the ACROFAST study

    Journal of the Endocrine Society, Vol. 10, Núm. 4

  2. Efficacy and safety of osilodrostat in patients with ectopic Cushing´s syndrome. a real-world study in Spain

    Journal of Endocrinological Investigation, Vol. 49, Núm. 4, pp. 819-831

  3. Glucocorticoid-Induced Positive Feedback in Cushing Disease: Insights From a Spanish Multicenter Cohort

    Endocrine Practice, Vol. 32, Núm. 6, pp. 878-886

  4. Growth Hormone Assay-Adjusted Standardization Reveals Distinct Clinical Phenotypes in Acromegaly

    Endocrine Practice, Vol. 32, Núm. 2, pp. 236-245

2025

  1. Executive summary of the consensus document for the management of severe Cushing's syndrome: Consensus document of the Neuroendocrinology Focus Group of the Spanish Society of Endocrinology and Nutrition (SEEN)

    Endocrinologia, Diabetes y Nutricion, Vol. 72, Núm. 10

  2. Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study

    Journal of Endocrinological Investigation, Vol. 48, Núm. 12, pp. 2857-2867

  3. Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas

    Endocrine Connections, Vol. 14, Núm. 7

  4. Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly

    Pituitary, Vol. 28, Núm. 6

  5. Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain

    Journal of Clinical Medicine, Vol. 14, Núm. 21

  6. Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors

    Journal of Clinical Endocrinology and Metabolism, Vol. 110, Núm. 12, pp. 3391-3399

2024

  1. Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases

    Journal of Clinical Endocrinology and Metabolism, Vol. 109, Núm. 12, pp. e2178-e2187

  2. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  3. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  4. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  5. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

  6. Personalized Medicine in Acromegaly: The ACROFAST Study

    The Journal of clinical endocrinology and metabolism, Vol. 110, Núm. 1, pp. 30-40

2023

  1. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

    Clinical Endocrinology, Vol. 99, Núm. 4, pp. 378-385

  2. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2014

  1. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study

    Clinical Endocrinology, Vol. 81, Núm. 6, pp. 883-890

2013

  1. Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish Acromegaly Registry (REA)

    Pituitary, Vol. 16, Núm. 1, pp. 115-121